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Is Your Pharmacy Participating?
By Sue Mears, RPh, Board Compliance Officer
During the 86th Iowa General Assembly, the Iowa legis-
lature approved a law that allows pharmacists to dispense 
naloxone to individuals who may be in a position to assist 
someone experiencing an opioid-related overdose. The 
state’s medical director, Dr Patricia Quinlisk, approved 
a statewide standing order for any pharmacy to use in 
order to provide this lifesaving medication. Iowa Board 
of Pharmacy rules were amended and became effective 
in November 2016. Since that time, the statewide order 
has been updated to include the newer formulation of the 
naloxone auto-injector. Also, the Recipient Eligibility 
Assessment form has had some updates, as recently as 
March 2017. If you are currently participating in the 
statewide standing order, please take a minute to review 
the updated forms on the Board’s website to ensure you 
are using the most current form. 
If you are not participating in the standing order, why 
not? Opioid abuse is a major problem, even in Iowa, and 
pharmacists are in a terrific position to provide assistance. 
If you are unsure of the need in your area, please take 
some time to check in with other providers or the police 
department in your local area. You may be surprised to 
find out the problem is in your backyard, too. 
In order to assist the public in finding participating 
locations, Board staff would like to be notified if your 
pharmacy is participating in the statewide standing order. 
Please send a note to Sue Mears at sue.mears@iowa.gov 
to let the Board know of your pharmacy’s participation.
Help Needed With USP Compliance 
Study
The Board needs your help with the largest and most 
comprehensive study of United States Pharmacopeia 
(USP) Chapters <797> and <800> compliance ever under-
taken in the United States! The 2017 USP <797> & <800> 
Compliance Study, led by sterile compounding experts 
and study directors Eric Kastango, MBA, RPh, FASHP, 
and Kate Douglass, MS, RN, CRNI, is now open. The 
study gives you the opportunity to perform a complete 
USP <797> and <800> gap analysis or answer questions 
related to just Chapter <797> or <800>, all from one login.
The study directors believe that the information and 
insights gained from this year’s study will be very valuable 
to the industry. These results will assist with benchmark-
ing progress and identify where additional resources and 
focus are required to continue to improve sterile com-
pounding practice and patient safety. For that reason, you 
are encouraged to participate.
The study uses a sophisticated, web-based gap analysis 
tool that Ms Douglass and Mr Kastango developed and 
have been using for the last several years. This tool is be-
ing made available at no charge to all study participants. 
It should be noted that all individual facility results are 
confidential – only aggregate data will be used in the 
study report. 
In return for your participation, you will receive a 
highly detailed action plan that is automatically gener-
ated based on your answers to the survey. This action 
plan provides documentation that can be used to begin 
or continue sterile compounding practice improvements 
at your location. The survey takes 60 to 90 minutes 
to complete, but does not need to be completed in one 
sitting. This year, the study team has also provided 
a pdf document of all the questions to facilitate off- 
line data collection for those who might find this useful. 
This will be available for download after you have regis-
tered and completed the first two informational sections 
of the survey.
Please register for the study today at http://797study 
.criticalpoint.info. Use survey code G797A. The study 
will remain open through June 30, 2017.
Thank you in advance for your participation in the 2017 
USP <797> & <800> Compliance Study. The results will 
help the Board learn more about the successes and challenges 
relative to USP <797> and <800> compliance. With that 
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ISMP list of high-alert medications. Many of the items included 
represent system improvements and safeguards that ISMP has 
recommended in response to analysis of medication errors 
reported to the ISMP Medication Errors Reporting Program, 
problems identified during on-site consultations with health care 
organizations, and guidelines in medical literature.
The self-assessment is divided into 10 key elements that most 
significantly influence safe medication use. Each element is 
defined by one or more core characteristics of a safe pharmacy 
system that further define a safe medication use system. Each 
core characteristic contains individual self-assessment items to 
help evaluate success with achieving each core characteristic.
ISMP recommends that each pharmacy site convene its own 
team of staff members (ie, pharmacist(s), technician(s), and stu-
dent pharmacist(s)) to complete this comprehensive assessment 
and use the information as part of its ongoing safety and quality 
improvement efforts. An online form has been provided to help 
participants organize and score their responses. Important: The 
self-assessment should be completed in its entirety by staff and 
managers who work within the pharmacy, not by off-site managers 
on behalf of the pharmacy.
When the self-assessment is completed, respondents can gen-
erate reports showing how their pharmacy answered each item 
and how they scored on each as a percentage of the maximum 
possible score. The pharmacy can then use its scores to identify 
and prioritize opportunities for its safety plan of action. 
ISMP is not a regulatory or standards-setting organization. As 
such, the self-assessment characteristics represent ideal practices 
and are not purported to represent a minimum standard of prac-
tice. Some of the self-assessment criteria represent innovative 
practices and system enhancements that are not widely available 
in pharmacies today. However, the value of these practices in 
reducing errors is grounded in expert analysis of medication 
errors, scientific research, or strong evidence of their ability to 
reduce errors.
To view, download, and print the PDF of the assessment, which 
includes the introduction, instructions for use, self-assessment 
items, and definitions, visit https://www.ismp.org/Survey/
NewMssacap/Index.asp.
CDC Publishes Resource to Foster Use of 
JCPP Pharmacists’ Patient Care Process
A publication intended to encourage the use of the Joint 
Commission of Pharmacy Practitioners (JCPP) Pharmacists’ 
Patient Care Process was released by the Centers for Disease 
Control and Prevention’s (CDC’s) Division for Heart Disease 
and Stroke Prevention. In Using the Pharmacists’ Patient Care 
Process to Manage High Blood Pressure: A Resource Guide 
for Pharmacists, CDC calls on pharmacists and other health 
care providers to implement the Pharmacists’ Patient Care 
Process model to reduce heart disease and stroke in the United 
States. Pharmacists can have a positive effect on population 
health by providing patient care services and participating in 
collaborative practice agreements and continuing education 
(CE) programs, notes the CDC publication. The publication 
is available at www.cdc.gov/dhdsp/pubs/docs/pharmacist-
resource-guide.pdf. 
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DEA Changes Registration Renewal Process
As of January 2017, Drug Enforcement Administration (DEA) 
will no longer send its second renewal notification by mail. Instead, 
an electronic reminder to renew will be sent to the email address 
associated with the DEA registration. 
In addition, DEA will retain its current policy and procedures 
with respect to renewal and reinstatement of registration. The 
policy is described below.
♦ If a renewal application is submitted in a timely manner
prior to expiration, the registrant may continue operations,
authorized by the registration, beyond the expiration date
until final action is taken on the application.
♦ DEA allows the reinstatement of an expired registration for
one calendar month after the expiration date. If the registration
is not renewed within that calendar month, an application for 
a new DEA registration will be required.
♦ Regardless of whether a registration is reinstated within the
calendar month after expiration, federal law prohibits the
handling of controlled substances or List 1 chemicals for any 
period of time under an expired registration.
Additional information is available on the DEA website at www 
.deadiversion.usdoj.gov/drugreg/index.html.
ISMP Medication Safety Self Assessment for 
Community/Ambulatory Pharmacy
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). 
ISMP is an independent nonprofit agency 
and federally certified patient safety organization that analyzes 
medication errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and other practitioners. 
ISMP then makes appropriate contacts with companies and 
regulators, gathers expert opinion about prevention measures, and 
publishes its recommendations. To read about the risk reduction 
strategies that you can put into practice today, subscribe to ISMP 
Medication Safety Alert!® Community/Ambulatory Care Edition 
by visiting www.ismp.org. ISMP provides legal protection and 
confidentiality for submitted patient safety data and error reports. 
Help others by reporting actual and potential medication errors to 
the ISMP National Medication Errors Reporting Program Report 
online at www.ismp.org. Email: ismpinfo@ismp.org.
Pharmacists in community and ambulatory settings can now 
access a newly revised tool that will help them review and improve 
their medication safety practices. The 2017 Institute for Safe 
Medication Practices (ISMP) Medication Safety Self Assessment® 
for Community/Ambulatory Pharmacy is designed to help pharma-
cies evaluate their current systems, proactively identify opportuni-
ties for improvement, and track their efforts over time.
An advisory panel of experts helped ISMP update items from 
the 2001 community/ambulatory self-assessment as well as add 
items to address new practices and processes, including the 
pharmacist’s evolving role in immunization administration. New 
research findings about error prevention and emerging technolo-
gies previously not widely adopted are also covered. 
 The self-assessment contains items that address the use of 
medications in the clinical setting, many of which are on the 
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The National Association of Boards of Pharmacy® (NABP®) 
is a member of JCPP and endorses the Pharmacists’ Patient 
Care Process. In its September 2015 newsletter (page 167), 
NABP discusses integrating the JCPP Pharmacists’ Patient 
Care Process to improve medication outcomes and promote 
consistency in patient care service delivery. Additional infor-
mation about JCPP is available at https://jcpp.net. 
FDA Issues Final Guidance on Repackaging 
Drugs by Pharmacies and Registered 
Outsourcing Facilities
In January 2017, Food and Drug Administration (FDA) 
issued a final guidance for industry titled, “Repackaging of 
Certain Human Drug Products by Pharmacies and Outsourcing 
Facilities.” This guidance describes the conditions under 
which FDA does not intend to take action for violations of 
certain provisions of the Federal Food, Drug, and Cosmetic 
Act when a state-licensed pharmacy, a federal facility, or an 
outsourcing facility repackages certain human drug products. 
The guidance is available at www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM434174.pdf.  
Electronic or written comments may be submitted at any time 
for this final guidance following the instructions provided in the 
Federal Register, which can be found at www.federalregister 
.gov/documents/2017/01/13/2017-00723/repackaging-of-
certain-human-drug-products-by-pharmacies-and-outsourcing-
facilities-final-guidance.
CriticalPoint Launches QP503A Certification 
Program for Sterile Compounding in 2017 
In 2017, CriticalPoint, LLC, launched its QP503A certifica-
tion program for sterile compounding personnel. Specifically, 
CriticalPoint is offering the QP503A Certification and the 
QP503A Master Certification, which may be earned after obtain-
ing the basic QP503A Certification. Participants will gain vital 
knowledge and skills to successfully plan, develop, and operate 
a 503A pharmacy sterile compounding operation. 
The QP503A Certification involves a didactic program of 
home study, live training, and practicum activities accompa-
nied by required objective personnel and cognitive testing. The 
QP503A Master Certification requires participants to demon-
strate their ability to apply their QP503A Certification training in 
actual work settings and produce measurable changes in sterile 
compounding processes resulting in improved patient safety.
Additional details about these programs and the certification 
requirements are available online at www.criticalpoint.info/
wp-content/uploads/CriticalPoint-QP503A-Certification.pdf. 
PTCB Suspends Implementation of Planned 
2020 Accredited Education Requirement for 
Pharmacy Technicians 
The Pharmacy Technician Certification Board (PTCB) is 
suspending the implementation of the accredited education re-
quirement for pharmacy technicians. In 2013, PTCB announced 
that the requirement would take effect in 2020, but PTCB has 
“determined that additional deliberation and research are needed 
to address stakeholder input, develop supporting policy, and 
conduct further study of technician roles,” said Larry Wagen-
knecht, BPharm, chair of the PTCB Board of Governors, and 
chief executive officer of the Michigan Pharmacists Association, 
in a news release. The role of pharmacy technicians is evolving, 
and PTCB is taking steps to support the pharmacy community. 
PTCB recently completed a job analysis study to collect data 
on current roles and responsibilities of pharmacy technicians 
across all practice settings to update PTCB’s Pharmacy Tech-
nician Certification Exam and is in the process of developing 
advanced certification programs. In addition, PTCB hosted 
an invitational conference in February 2017 where pharmacy 
leaders and stakeholders examined entry-level standards and 
provided information to help determine future plans for imple-
menting PTCB program changes.
PTCB’s news release is available at www.ptcb.org in the 
News Room section.
ASOP Global Spreads Awareness About 
Illegal Online Drug Sellers and Counterfeit 
Medications
Alliance for Safe Online Pharmacies (ASOP Global) part-
nered with several nonprofit organizations, including NABP, 
to launch a campaign to raise awareness of illegal online drug 
sellers and counterfeit medications. The campaign encourages 
dialogue among health care providers and patients regarding 
where patients purchase their medications, especially if pa-
tients are buying them online.
After offering the CE course “Internet Drug Sellers: What 
Providers Need to Know” to over 1,000 health care providers, 
ASOP Global found that less than 10% of providers reported 
they were “very aware” counterfeit prescription drugs are being 
sold on the internet and only 1.4% said they regularly discuss 
the risks of illegal internet drug sellers with patients. ASOP 
Global Executive Director Libby Baney said, “After complet-
ing the course, however, there was a ten-fold increase in the 
expected frequency in which providers planned to discuss the 
risks associated with buying prescription medicines online 
with their patients and what they can do to avoid physical 
and financial harm.” 
For more information about the campaign, visit www 
.BuySafeRx.pharmacy. 
New Interactive Map Tracks Pharmacist 
Vaccination Laws
A new resource – an interactive 50-state map tracking 
pharmacist vaccination laws between 1990 and 2016 – was 
published by The Policy Surveillance Program, A LawAtlas 
Project. The map, which is available at http://lawatlas.org/
datasets/pharmacist-vaccination, explores laws that give 
pharmacists authority to administer vaccines and establish 
requirements for third-party vaccination authorization, patient 
age restrictions, and specific vaccination practice requirements, 
such as training, reporting, record keeping, notification, 
malpractice insurance, and emergency exceptions. The Policy 
Surveillance Program is administered by Temple University 
Beasley School of Law.
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 insight, it becomes easier to target additional strategies 
to promote best-practice sterile compounding. The re-
sults of the study will be published this fall in Pharmacy 
Purchasing & Products.
If you have any questions, please contact the study team 
at studyteam@797study.com.
CARA 2016 – Partial Filling of a Schedule II
By Sue Mears, RPh, Board Compliance Officer
In July 2016, US Congress passed the Comprehensive 
Addiction and Recovery Act (CARA), which President 
Obama signed into law. The law adds a provision that al-
lows pharmacists to partially fill any Schedule II prescrip-
tion at the request of the prescriber or the patient, as long 
as state law does not prohibit such partial filling. CARA 
language allows the remaining portion of the partially 
filled prescription to be filled within 30 days of the date 
the prescription was issued.
Currently, Iowa Code would not prohibit such partial 
filling, but the Board’s rules do not have a specific provi-
sion to allow the filling of the remaining portion of the 
prescription at this time. The Board is in the process of 
reviewing and updating Chapter 10 and plans to include 
the CARA language. While the Board’s rule currently does 
not specifically identify this scenario for partial filling of 
a Schedule II prescription, a pharmacy that is complying 
with the provisions in CARA would not be in conflict 
with Iowa Code or Board rules.
New Database on the Way for Board of 
Pharmacy – Update!
Board executive and administrative staff, via the Iowa 
Department of Administrative Services (DAS), has iden-
tified a vendor to supply and configure a new licensing 
database to meet the technological needs of the public as 
well as Board staff. A Notice of Intent to Award was sent 
by DAS to iGov Solutions, LLC (Lake Mary, FL) on April 
7, 2017. The Board hopes to begin implementation and data 
migration in the coming months. The Board projects that 
pharmacists due to renew their licenses in June 2018 will 
be able to do so online.  
Iowa 2017 Legislative Update
The Iowa legislature has concluded its 2017 session. The 
following bills have been passed and signed into law that 
may be of interest to the pharmacy community:
 ♦ Senate File (SF) 484 was the Board’s proposed bill 
to amend Iowa Code 155A, which would permit the 
Board to designate alternate Board members to serve 
during contested case proceedings when a quorum 
of the Board is unable to be obtained. This bill also 
removed the spending cap placed on the Board’s 
prescription drug take-back program.
 ♦ SF 332 was the Board’s proposed bill to amend Iowa 
Code 124 to incorporate federal schedule changes 
into Iowa law. This included the transition of tra-
madol from legend status to Schedule IV status and 
hydrocodone-containing products from Schedule 
III status to Schedule II. Practically speaking, this 
legislative change will not impact the practice of 
pharmacy in Iowa, since these products have already 
been designated to these statuses at the federal level.
 ♦ House File 524 amends Iowa Code 124 to expand 
prescription monitoring program information shar-
ing to any state (currently, information is only shared 
with bordering states and Kansas). This bill also ex-
pands medical cannabidiol to treat multiple disease 
states, and allows up to two manufacturers and five 
dispensaries in Iowa.
Follow the Board on Facebook and 
Twitter
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